Of note, our data show that in the absence of MICL (or inhibition of receptor function by anti-MICL antibodies), the PAD4 pathway becomes activated during autoimmune disease, leading to dysregulated NET formation and aberrant inflammation. The gene discussed is CLEC12A; the disease is autoimmune disease.